Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

Author's Avatar
Dec 06, 2022

PAS-003 is a first in class monoclonal antibody targeting Alpha 5 Beta 1 integrin as a treatment for amyotrophic lateral sclerosis (ALS) and other neuroinflammatory-driven CNS diseases